

**NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR ANY JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE UNLAWFUL.**

**NOTICE RELATING TO STABILIZATION TRANSACTIONS PURSUANT TO ARTICLE 5(4) OF REGULATION (EU) NO 596/2014 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF 16 APRIL 2014 AS WELL AS ARTICLE 6(2), (3) AND ARTICLE 8 OF COMMISSION DELEGATED REGULATION (EU) NO 2016/1052 OF 8 MARCH 2016**

17 October 2018

## RELEVANT NOTICE

### LABORATORIOS FARMACÉUTICOS ROVI, S.A.

#### Post-Stabilisation Period Announcement

Pursuant to article 228 of the Spanish Securities Market Act (Royal Legislative Decree 4/2015, of 23 October) and article 6.3 of Commission Delegated Regulation (EU) 2016/1052, of 8 March 2016 (the "**Delegated Regulation (EU) 2016/1052**"), and further to the pre-stabilisation period announcement dated 4 October 2018 (official registry number 270232), Jefferies International Limited, in its capacity as stabilising agent in connection with the capital increase excluding the pre-emptive subscription rights (*derechos de suscripción preferente*) of the existing shareholders of Laboratorios Farmacéuticos Rovi, S.A. (the "**Issuer**" or the "**Company**"), hereby informs that it has not undertaken any stabilisation transactions in relation to said shares on the Madrid, Barcelona, Bilbao and Valencia Stock Exchanges, over the counter and other trading venues.

Jefferies International Limited exercised on 17 October 2018 in full the over-allotment option to subscribe up to 551,724 newly issued ordinary shares in the Company at the offer price (€14.50 per share) granted to Jefferies International Limited by the Issuer.

Following said exercise of the over-allotment option, the stabilising period (initially expected to conclude on 7 November 2018) is hereby terminated as of the date hereof.

---

Jefferies International Limited

Name: Luca Erpici

Position: European Head of Equity Syndicate

# Jefferies

This announcement is for information only and does not constitute an offer or invitation to underwrite, subscribe for or otherwise acquire or dispose of any securities or investment advice in any jurisdiction in which such an offer or solicitation is unlawful, including without limitation, the United States, Australia, Canada, or Japan. Any failure to comply with these restrictions may constitute a violation of the securities laws of such jurisdictions.

This announcement and the information contained herein, is not an offer of securities for sale in, and is not for transmission to or publication, distribution or release, directly or indirectly, in the United States of America (including its territories and possessions, any state of the United States of America and the District of Columbia) (the "United States"). The securities being offered have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"), or under any applicable securities laws of any state or other jurisdiction of the United States and may not be offered, sold, resold, transferred or delivered, directly or indirectly, in the United States unless registered under the Securities Act or pursuant to an exemption from, or in a transaction not subject to, such registration requirements and in accordance with any applicable securities laws of any state or other jurisdiction of the United States. No public offering of the securities discussed herein is being made in the United States.

Jefferies International Limited ("Jefferies") is authorised and regulated by the Financial Conduct Authority, is acting for the Company only in connection with the offer and will not be responsible to anyone other than the Company for providing the protections offered to clients of Jefferies, nor for providing advice in relation to the offer or any matters referred to in this communication.